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Possible Roles of Epidermal Opioid Systems
in Pruritus of Atopic Dermatitis
Mitsutoshi Tominaga1, Hideoki Ogawa1 and Kenji Takamori1,2
The m-opioid (b-endorphin/m-opioid receptor) and k-opioid (dynorphin A (DynA)/k-opioid receptor) systems
play pivotal roles in the modulation of pruritus in the central nervous system. The m-opioid system has also been
identified in human epidermis, raising the possibility that the system controls the peripheral itch. However, the
precise distribution of the k-opioid system has not yet been clarified in human epidermis. To address this issue,
reverse transcription-PCR and immunohistochemical analyses were performed on cultured keratinocytes and
normal skins from humans. The analyses revealed that epidermal keratinocytes express k-opioid receptor and
its ligands, DynA (1–17) and DynA (1–8). Moreover, expression for m- and k-opioid systems was examined
immunohistochemically in skin biopsies from healthy volunteers and patients with atopic dermatitis (AD)
before and after psoralen-ultraviolet A (PUVA) therapy. Our expression analyses showed that only the k-opioid
system, not the m-opioid system, was downregulated in the epidermis of AD patients. The downregulation of
the m-opioid system and the restoration of the k-opioid system by PUVA therapy were observed in the AD
patients, concomitant with a decrease of VAS (visual analogue scale) scores. These results suggest epidermal
opioid systems are associated with the modulation of pruritus in AD. This new finding may help us to
understand the control mechanism of peripheral itch.
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INTRODUCTION
Endogenous opioid peptides and opiates, like morphine,
transmit their pharmacological effects through membrane-
bound opioid receptors, which belong to the family of
G-protein-coupled receptors (Tseng, 1995). Pharmacological
studies and molecular cloning have led to the identification
of three major types of opioid receptors, m-type (MOR),
k-type (KOR), and d-type (Satoh and Minami, 1995; Zadina
et al., 1999; Stefano et al., 2000). They primarily differ in the
affinity for various opioid ligands such as MOR is a receptor
for b-endorphin (b-end), KOR is a receptor for dynorphins,
and d-type is a receptor for enkephalins (Goldstein and
Naidu, 1989; Tseng, 1995).
Opioid-induced pruritus is a well-known side effect in pain
treatment with morphine and other MOR agonists in humans
(Cousins and Mather, 1984; Ballantyne et al., 1988). In
contrast, MOR antagonists (e.g., naloxone and naltrexone) are
known to suppress pruritus in patients with chronic cholestasis,
chronic renal failure, and atopic dermatitis (AD) (Bergasa
et al., 1992; Peer et al., 1996; Metze et al., 1999; Greaves,
2005). These findings suggest that the m-opioid system has a
role in the itching. In addition, it has been recently reported
that the activation of KOR antagonizes various MOR-mediated
actions but not the analgesic action (Bodnar and Klein, 2006).
Nagase et al. (1998) have discovered a novel KOR agonist,
nalfurafine/TRK-820. When the compound is administered
subcutaneously or orally, the antipruritic activity was demon-
strated in morphine-, histamine-, and substance P-induced
animal scratching models (Togashi et al., 2002; Umeuchi
et al., 2003; Wakasa et al., 2004). Therefore, these studies
suggest that the m-opioid system is itch-inducible, whereas the
k-opioid system is itch-suppressive.
Expression analyses of opioid receptors show that normal
human epidermal keratinocytes (NHEKs) express a functionally
active MOR (Bigliardi et al., 1998; Bigliardi-Qi et al., 2000) as
well as primary afferent neurons (Stander et al., 2002).
Additionally, the MOR expression alters in epidermis and
nerve endings of chronic AD (Bigliardi-Qi et al., 2005). It has
been speculated that internalization of the MOR in the
epidermis of patients with AD may lead to the availability of
free opioid ligands, which then induce chronic pruritogenic
signals via altered unmyelinated nerve C-fibers. However, the
role of non-neuronal opioid receptors for the modulation of
pruritus is as yet unclear. On the other hand, KOR is detected in
fibroblast and mononuclear cells of normal human skin (Salemi
et al., 2005) but has not yet been identified in the epidermis.
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This study examines the distribution of KOR and
dynorphin A (DynA) in normal human epidermis. Moreover,
this report describes the immunohistological features of
m- and k-opioid systems in skin biopsies obtained from AD
patients before and after psoralen-ultraviolet A (PUVA)
therapy.
RESULTS
Expression of MOR and KOR in cultured keratinocytes
To examine whether keratinocytes express transcripts for
MOR and KOR genes, reverse transcription-PCR (RT-PCR)
analysis was conducted on cultured HaCaT cells and NHEK
(Figure 1a). Transcripts for MOR and KOR genes were
expressed in both HaCaT cells and NHEK. In addition, these
genes were expressed in normal human skin.
Immunocytochemical analysis on cultured HaCaT cells
and NHEK was carried out to evaluate that MOR and KOR
were expressed on the protein level. The specificities of
antibodies to these opioid receptors were validated in Figure
S1. In MOR staining, the strong immunoreactivity was
observed in plasma membrane of HaCaT cells (Figure 1b)
and NHEK (Figure 1c). Immunoreactivity for KOR was
detected in HaCaT cells (Figure 1d) and NHEK (Figure 1e),
and the receptor was primarily localized in plasma mem-
brane of the cells. The immunoreactivities for MOR and KOR
were also faintly detected in the cytoplasm of these cultured
cells.
Distribution of MOR and KOR in normal human skin
RT-PCR analysis showed that both MOR and KOR genes
were expressed in normal human skin. Therefore, the
distribution of MOR and KOR was examined immunohisto-
chemically in normal human skin. MOR expression was
observed throughout the epidermis (Figure 2a). Similarly,
KOR was expressed in epidermal keratinocytes of the skin
(Figure 2b). Some cells expressing MOR or KOR were
presented in the dermis. The omission of the primary
antibodies but inclusion of secondary antibodies did not
produce any specific staining (data not shown). However, the
immunoreactivities in the stratum corneum were detected
with normal rabbit IgG and normal goat IgG (Figure 2c and
d). Therefore, the staining pattern may be nonspecific
immunoreaction by the primary antibodies.
Distribution of b-end and DynAs in human epidermis
Proopiomelanocortin (POMC) is the precursor of b-end
(Smith and Funder, 1988; Autelitano et al., 1989), while
prodynorphin (PDYN) is the precursor of DynA (1–17) and
DynA (1–8) (Civelli et al., 1985). In RT-PCR analysis, the
transcripts for POMC and PDYN genes were detected in
normal human skin and cultured NHEK (Figure S2).
b-end and DynAs bind with high affinity to MOR and
KOR, respectively (Gilmore and Weiner, 1989; Nock et al.,
1990; Kinouchi and Pasternak, 1991; Konkoy and Childers,
1993; Bigliardi-Qi et al., 2000). Therefore, the distribution of
b-end, DynA (1–17), and DynA (1–8) in normal epidermis was
examined by double-immunolabeling studies with antibodies
to keratin 14 (K14) and K10. No immunoreactivity for b-end
was observed in the basal layer (Figure 3a), whereas it was
strongly detected in the suprabasal layer (Figure 3b).
Immunoreactivity for DynA (1–17) was confined to
the basal layer (Figure 3c) but not in the suprabasal layer
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Figure 1. Expression analyses of MOR and KOR in cultured keratinocytes.
(a) Total RNA was isolated from cultured keratinocytes or normal human skin,
and RT-PCR analysis was conducted with primers specific for MOR and KOR
genes. Lanes 1 and 2 were positive controls for expression of these genes
(Supplementary Data). Lane 1, Mu-CHO; lane 2, Kappa-CHO; lane 3, HaCaT
cells; lane 4, NHEK; lane 5, normal human skin. b-actin was used as an
internal control for mRNA intensity and quality. Immunostaining for MOR
(green) showed that the immunoreactivity was primarily detected in the
plasma membrane of (b) HaCaT cells and (c) NHEK. Some cells were negative
for anti-MOR antibody (arrows in panel c). Immunostaining for KOR (red)
showed that the receptor was localized in the plasma membrane of (d) HaCaT
cells and (e) NHEK. Nuclei were counterstained with 40,60-diamidino-2-
phenylindole hydrochloride (DAPI) (blue). Bars (b, d)¼30 mm; (c, e)¼ 75 mm.
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(Figure 3d). In contrast, immunoreactivity for DynA (1–8) was
present throughout the epidermis but was more prominent in
the suprabasal layer than the basal layer (Figure 3e and f).
Expression changes of epidermal opioid systems in AD patients
before and after PUVA therapy
Expression of MOR and KOR in skins of AD patients before
and after PUVA therapy, an established treatment for many
skin disorders (Henseler et al., 1981), was examined by
immunohistochemistry. Skin biopsies used in this experiment
were taken from AD patients before and after PUVA therapy,
and visual analogue scale (VAS) scores were significantly
decreased in the treated group (Figure 4a). In comparison
with healthy volunteers, expression level of MOR was
unchanged in the epidermis of AD patients. On the other
hand, the MOR expression was decreased in the epidermis
after PUVA therapy (Figure 4b and d). Contrary to the MOR
expression, the epidermal KOR level was decreased in the
AD patients compared with that in healthy volunteers. The
epidermal KOR level was unchanged in the AD patients
before and after PUVA therapy (Figure 4c and e).
We investigated additionally if expression patterns of
b-end and DynAs alter in the epidermis of AD patients before
and after PUVA therapy. In comparison with healthy
volunteers, the expression level of epidermal b-end was
unchanged in the AD patients before and after PUVA therapy
(Figure 5a and d). On the other hand, expression levels of
DynA (1–17) and DynA (1–8) were decreased in the epidermis
of AD patients compared with those in healthy volunteers,
and they tended to return to the normal control levels by
PUVA therapy (Figure 5b, c, e, and f).
DISCUSSION
In this study, we found that cultured human keratinocytes
expressed the transcripts for KOR genes as well as MOR genes.
Additionally, immunofluorescence studies using a specific
anti-KOR antibody showed that the receptor was expressed in
epidermal keratinocytes in situ and in vitro. The expression
was also observed in some dermal cells except for keratino-
cytes, and they may be dermal fibroblast and mononuclear
cells, as described previously (Salemi et al., 2005).
PDYN, the precursor of DynAs, has a signal peptide at the
N terminus (Civelli et al., 1985). Our RT-PCR analysis
showed that the transcripts for PDYN gene were detected in
cultured keratinocytes. These data suggest that PDYN are
produced and secreted from epidermal keratinocytes. The
secreted PDYN is cleaved by prohormone convertases, and
thereby DynA (1–17) is produced (Tseng, 1995). The
formation of DynA (1–8) is also specifically due to the
cleavage of its precursor DynA (1–17) by prohormone
convertase 2 (Day et al., 1998). We revealed that these
prohormone convertases are expressed in epidermal kerati-
nocytes (data not shown). In addition, DynA (1–17) and DynA
(1–8) were distributed in the epidermis. These results imply
that keratinocytes can produce the DnyAs in the skin.
The DynAs bind with high affinity to KOR, a G-protein-
coupled receptor (Kinouchi and Pasternak, 1991; Konkoy and
Childers, 1993). Several reports have characterized the
signal-transduction events initiated by KOR activation. By
coupling to the G-protein Gai/o, KOR inhibits adenylate
cyclase, increases potassium conductance, decreases cal-
cium conductance, and mobilizes intracellular calcium
(Tseng, 1995). Recently, KOR has been recognized to
activate the extracellular signal-regulated kinase in neural
cells (Bohn et al., 2000; Belcheva et al., 2005). This
activation has been demonstrated to persist for several hours
following agonist treatment, suggesting a role for KOR in
long-term growth and gene regulation. Moreover, KOR can
activate extracellular signal-regulated kinase via a protein
kinase C isoform, secondary messengers, and a heterologous
desensitization event different from MOR in neural cells
(Bohn et al., 2000; Belcheva et al., 2005). We found that both
KOR and MOR are coexpressed in keratinocytes of normal
skins (data not shown). Therefore, these data may suggest the
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Figure 2. Immunostaining for MOR and KOR in normal human skin. (a) Double-labeling for MOR (green) and collagen type IV (red) was performed in
normal human skin. Immunoreactivity for MOR was mainly detected in epidermal keratinocytes and some dermal cells. (b) Double-labeling for KOR (red)
and collagen type IV (green) in normal human skin showed that the receptor was expressed in epidermal keratinocytes and some dermal cells. In negative
control experiments using (c) normal rabbit IgG and (d) normal goat IgG, nonspecific immunoreactivities were detected in the stratum corneum.
Bar¼37.5 mm. epi: epidermis; der: dermis.
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distinct signaling mechanisms between these opioid recep-
tors in epidermal keratinocytes.
In our experiments, MOR and b-end were mainly
distributed in normal epidermis, as described previously
(Bigliardi et al., 1998; Kauser et al., 2003; Bigliardi-Qi et al.,
2004). The b-end stimulates the keratinocyte migration
in vitro (Bigliardi et al., 2002). More recently, Bigliardi-Qi
et al. (2007) reported that epidermal hypertrophy and
densities of peripheral nerve fibers were altered in MOR
and KOR knockout mice. These observations suggest that
m- and k-opioid systems function in not only the nervous
system but also skin tissue.
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Figure 4. Expression patterns of MOR and KOR in skins of AD patients
before and after PUVA therapy. (a) VAS scores were significantly decreased
in the AD patients after PUVA therapy, compared with before the therapy
(*Po0.01). (b) Double-labeling for MOR (green) and collagen type IV (red)
was performed in skins of healthy volunteers and AD patients before and after
PUVA therapy. Expression of MOR in the epidermis of AD patients was at the
same level as healthy volunteers. After PUVA therapy, decreased expression
of the receptor was observed in the epidermis. (c) Double-labeling for KOR
(red) and collagen type IV (green) was performed in skins of healthy
volunteers and AD patients before and after PUVA therapy. In comparison
with healthy volunteers, KOR expression was decreased in the epidermis of
AD patients. The expression level of KOR was unchanged in the AD patients
before and after PUVA therapy. Nuclei in each panel were counterstained
with 40,60-diamidino-2-phenylindole hydrochloride (DAPI) (blue).
Bar¼75 mm. epi: epidermis; der: dermis. Fluorescence intensity per unit area
of epidermal (d) MOR and (e) KOR was calculated in each group, and
statistical analysis was performed (*Po0.01; #P40.05).
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Figure 3. Distribution patterns of b-end and DynAs in normal human skin.
Double-labeling with antibodies to opioid peptides (b-end, DynA (1–17), and
DynA (1–8)) and keratins (K14 and K10) was carried out in normal human
skin. (a) The K14-positive cell layer was negative for b-end in the epidermis.
(b) The pattern of b-end staining was overlapped with the pattern of K10
staining in the epidermis. Immunoreactivity for DynA (1–17) was mainly
detected (c) in the K14-positive cell layer but not (d) in the K10-positive cell
layer. (e) Immunoreactivity for DynA (1–8) was weakly detected in the
K14-positive cell layer, (f) whereas the staining pattern corresponded
predominantly to that of K10. The white dotted line in each panel indicates
the border between the epidermis and the dermis (basement membrane).
Bar¼75 mm. epi: epidermis; der: dermis.
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The pharmacology of nalfurafine/TRK-820 has been
examined extensively. It is characterized as a chemically
novel, centrally penetrating, selective agonist at KOR. Non-
sedating doses of nalfurafine/TRK-820 inhibited the scratch-
ing behavior in mice elicited by histamine, substance P
(Togashi et al., 2002), or morphine (Umeuchi et al., 2003).
The antipruritic activities were antagonized by pretreatment
with nor-BNI, a selective KOR antagonist (Togashi et al.,
2002; Umeuchi et al., 2003). It is therefore reasonable to
conclude that KOR is involved in mediating the antipruritic
effects of nalfurafine/TRK-820.
Chloroquine, a popular antimalarial agent, provokes an
often-intolerable side effect-generalized pruritus. Inan and
Cowan (2004) have validated the antipruritic effects of
nalfurafine/TRK-820 against chloroquine-induced scratching
in mice. Interestingly, the scratching behavior was also
antagonized by the peripherally restricted KOR agonist, ICI
204448. In addition, our preliminary experiments using NC/
Nga mice with AD-like dermatitis induced by 2,4-dinitro-
fluorobenzene showed that the topical application of
nalfurafine/TRK-820 in the skin inhibited the scratching
behavior in treated mice, but no sedating effects were
observed (unpublished observations). These data raise the
possibility of the antipruritic effects of KOR agonists at the
peripheral level. On the other hand, it is now generally
accepted that the m-opioid system is centrally itch-inducible
(Metze et al., 1999; Greaves, 2005). A recent study has
demonstrated that the topical application of MOR antagonists
in the skin inhibited the pruritus in AD patients (Bigliardi
et al., 2007), indicating that MOR antagonists have anti-
pruritic effects on peripheral itch.
Our expression analyses showed that only the k-opioid
system, not the m-opioid system, was downregulated in the
epidermis of AD patients. Bigliardi-Qi et al. (2005) have
described the downregulation of epidermal MOR expression
in AD patients. This discrepancy may be due to the different
immunohistochemical methods or the different antibody
reactivities. The authors have also demonstrated the MOR
internalization in the epidermis of AD patients by immuno-
staining with a permeabilization method. In our immuno-
staining method, the treatment was not conducted when
the skin was stained with antibodies, which recognizes
the extracellular domains of opioid receptors. Therefore,
although we could not exclude the penetration of antibodies
into the cells completely, many opioid receptors detected
by our immunostaining are localized on the plasma
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Figure 5. Expression patterns of b-end and DynAs in skins of AD patients before and after PUVA therapy. Skins of healthy volunteers and AD patients
before and after PUVA therapy were stained with antibodies to b-end, DynA (1–17), and DynA (1–8). (a) The expression level of b-end in the epidermis of
AD patients before and after PUVA therapy remained unchanged compared with that of healthy volunteers. (b, c) In contrast, DynA (1–17) and DynA
(1–8) expressions were decreased in the epidermis of AD patients, and the expression levels tended to return to the normal control levels after PUVA
therapy. The white dotted line in each panel indicates the border between the epidermis and the dermis (basement membrane). Bar¼ 75 mm. epi:
epidermis; der: dermis. Fluorescence intensity per unit area of epidermal (d) b-end, (e) DynA (1–17), and (f) DynA (1–8) was calculated in each group,
and statistical analysis was performed (*Po0.01; **Po0.05; #P40.05).
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membrane of epidermal keratinocytes, suggesting that they
are functionally active.
Moreover, the downregulation of MOR expression was
observed in the epidermis after PUVA therapy. Epidermal
KOR expression was unchanged in the AD patients before
and after PUVA therapy. However, elevated levels of
epidermal DynAs were observed in the treated group. This
result raises the possibility that the function of the epidermal
k-opioid system is restored by PUVA therapy. The down-
regulation of the m-opioid system and the restoration of the
k-opioid system were also concomitant with the decrease of
VAS scores in the treated group. Therefore, although the roles
of opioid systems for pruritus are controversial (Bigliardi-Qi
et al., 2007, it could be speculated that the m-opioid system
has a role in the induction of itch and the k-opioid system has
a role in the suppression of itch in the peripheral level. This
may help to explain why the pruritus is controlled by
treatments with opioid agonists or antagonists at the
peripheral level. Another possibility is that the opioid
receptors on peripheral nerve fibers are directly linked to
the modulation of peripheral itch, as well as the central itch.
This idea is supported by previous studies that suggest sensory
neurons express MOR and/or KOR (Stander et al., 2002;
Bigliardi-Qi et al., 2005; Rau et al., 2005).
The expression of the epidermal opioid system controlled
by PUVA was observed in this study. In mammalian neurons,
gene expression of opioid receptors is regulated by chromatin
remodeling and various transcription factors such as activator
protein-1 and poly(C) binding protein (Borner et al., 2002;
Kim et al., 2004, 2005; Park et al., 2005). The psoralen
functions by interfering with activator protein-1 in murine
keratinocytes, and thereby inhibits the DNA binding of
activator protein-1 (Martey et al., 2005). Others have
reported that the chromatin structure in human epithelial
cells is affected by PUVA (Ree et al., 1981; Gasparro et al.,
1997), and the change of chromatin structure influences the
DNA binding activity of transcription factors (Park et al.,
2005). These studies may explain the mechanism of PUVA-
regulated gene expression in epidermal keratinocytes.
The non-neuronal opioid receptors possibly influence the
cytokine pattern of keratinocytes (Slominski et al., 2000) or
the production of pruritogenic mediators from keratinocytes
(Andoh et al., 2004). In preliminary experiments using
cultured keratinocytes, we examined with quantitative RT-
PCR analysis whether expression levels of pruritogenic
cytokines such as IL-1, IL-2, and tumor necrosis factor-a are
changed by opioid peptides, but no significant differences in
these expressions between the cells cultured with and
without opioid peptides were observed (unpublished ob-
servations). Therefore, it will be necessary to carry out
comprehensive screenings for other cytokines and prurito-
gens, which are controlled by these opioid systems.
In conclusion, the precise distribution of the k-opioid
system in human epidermis was demonstrated for the first
time in this study. Additionally, our data suggest that
epidermal opioid systems are involved in the modulation of
pruritus in AD. These findings may expand the knowledge of
the effective treatment for pruritus of AD.
MATERIALS AND METHODS
Skin biopsies
Three-millimeter punch biopsies were taken with informed consent
from normal abdominal skins of 8 healthy male volunteers (age
range, 20–42 years; mean age, 30.6 years) and lesional abdominal
skins of 10 male patients (age range, 20–44 years; mean age, 29.1
years) with clinical appearance of chronic AD.
The AD patients were treated with PUVA, and skin biopsies were
also obtained from the same subjects. The therapy was performed
with oral administration of 0.6 mg/kg of 8-methoxypsoralen, and
UVA irradiation was given by a DERMARAY (Toko Electric
Corporation, Tokyo, Japan) at 2–6 J/cm2. The clinical skin conditions
were evaluated by clinical and VAS scores. The medical ethical
committee of the Juntendo University Urayasu Hospital approved all
described studies. This study was conducted according to the
Declaration of Helsinki Principles.
Cell culture
HaCaT cells (Boukamp et al., 1988) were maintained as monolayers
in DMEM (Sigma, St Louis, MO) containing heat-inactivated fetal
bovine serum at 10% supplemented with 50 U/ml penicillin and
50 mg/ml streptomycin at 371C, 5% CO2. NHEK was purchased from
Cambrex (Walkersville, MD). They were maintained according to
the company’s recommendations.
Antibodies
Primary antibodies used in this study were as follows: rabbit anti-
MOR (1:200; Santa Cruz Biotechnology, Santa Cruz, CA), goat anti-
KOR (1:100; Santa Cruz Biotechnology), rabbit anti-b-end (1:200;
Chemicon, Temecula, CA), rabbit anti-DynA (1–17) (1:200; Bachem,
Bubendorf, Switzerland), rabbit anti-DynA (1–8) (1:200; Bachem),
mouse anti-collagen type IV (1:20; Progen Biotechnik GmbH,
Heidelberg, Germany), mouse anti-K10 (1:10; Progen Biotechnik
GmbH), guinea-pig anti-K14 (1:200; Progen Biotechnik GmbH).
Secondary antibodies conjugated with Alexa 488 or Alexa 594 used
in this study were obtained from Molecular Probes (Eugene, OR).
Immunofluorescence staining
Immunocytochemistry. Cells were fixed with 4% paraformalde-
hyde in 0.1 M phosphate buffer (PB, pH 7.4) for 10 minutes. They
were washed three times with phosphate-buffered saline (PBS, pH
7.4) for 5 minutes and were blocked in PBS with 5% normal donkey
serum (Chemicon) and 2% BSA (Sigma) for 1 hour at room
temperature. Cells were overlaid with primary antibodies at working
dilutions and incubated for 16 hours at 41C. After washing with PBS,
the cells were incubated with secondary antibodies for 1 hour at
room temperature. After washing with PBS, they were mounted in
vectashield mounting medium with 40,60-diamidino-2-phenylindole
hydrochloride (Vector Laboratories Ltd, Peterborough, UK). Immuno-
labeling controls were performed by omitting primary antibodies
in the procedure. Immunoreactivity was viewed with a confocal
laser-scanning microscope DMIRE2 (Leica, Wetzlar, Germany).
Immunohistochemistry. Human skins were fixed with 4%
paraformaldehyde in 0.1 M PB for 4 hours. After washing with PBS,
they were immersed successively in PBS solution containing 10, 15,
and 20% sucrose. After the skins were embedded in optimal cutting
temperature (O.C.T.) compound (Sakura Finetechnical Co., Ltd.,
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Tokyo, Japan) and frozen in liquid nitrogen, cryosections (thickness
7mm) were cut using a CM1850 cryostat (Leica). They were mounted
on silane-coated glass slides. After blocking in PBS with 5% normal
donkey serum and 2% BSA, the sections were incubated with
antibodies against opioid receptors for 16 hours at 41C. In immuno-
fluorescence staining for opioid peptides, cryosections were fixed with
ice-cold acetone for 10 minutes at 201C. They were rehydrated in
PBS, and blocked in PBS with 5% normal donkey serum and 2% BSA.
The sections were incubated with antibodies against opioid peptides
for 16 hours at 41C. After washing with PBS, secondary antibodies
were added to the sections for 1 hour at room temperature, as
described above. As negative control experiments, the primary
antibodies were either omitted or replaced with normal IgG.
Total RNA preparation
Cultured cells were suspended in TRIZOL solution (Invitrogen,
Carlsbad, CA) and processed to purify total RNA following the
manufacturer’s protocol. Total RNA from human skins was isolated
with Rneasys Fibrous Tissue Mini Kit (Qiagen KK, Tokyo, Japan),
according to the manufacturer’s protocol. Universal Human
Reference RNA (UHR RNA, Stratagene, La Jolla, CA) was used as
a positive control for RT-PCR.
RT-PCR analysis
RT reaction was performed with random primers and ExScript Rtase
(all from TaKaRa, Kyoto, Japan). RT-PCR analysis was performed
using the ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems, Foster, CA). The primers used in this study are listed in
Table S1. They were designed to meet specific criteria and were
synthesized by Perfect Real Time support system (TaKaRa). The RT-
PCR mixture consisted of 0.2 mM of each primer, 1 SYBRs Premix
EX TaqTM (Perfect Real Time) premix reagent (TaKaRa), and 50 ng
cDNA to a final volume of 25 ml. The PCR was performed with 40
cycles (denaturation at 951C for 5 seconds, primer annealing and
elongation at 601C for 30 seconds). The PCR specificity was
confirmed by dissociation curve analysis and gel electrophoresis.
b-actin was used as an internal control for mRNA intensity and
quality. The RT-PCR analyses were repeated at least three times.
Semiquantitative measurements and statistical analyses
To semiquantify fluorescent intensity levels, at least five confocal
images were analyzed per skin biopsy in each experiment. Exposure
and acquisition setting were fixed and were such that no signal
saturation occurred. The total fluorescence intensity in the epidermis
of each skin biopsy was measured using Leica Confocal Software
(Leica), and fluorescence intensity per unit area was calculated. All
values were presented as mean7SD from three experiments.
Statistical analyses were performed by two-tailed Student’s t-test
and one-way analysis of variance with the Bonferroni’s multiple
comparison test.
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